The Integrated Forecasting and Analysis Tool   Login Now

Adolor

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Adolor are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Adolor, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Adolor - ADL5859 Central Nervous System Non-narcotic analgesics Delta opioid agonist Phase II   - ADL5747 Central Nervous System Non-narcotic analgesics Delta opioid agonist Phase I

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Adolor   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 246 246        PE Ratio (diluted) - Normalised (x) (3.7) (3.4)        Valuing the Enterprise        Enterprise Value 79 79        Free Cash Flow (Pre-Dividends) (60) (65)        FCF Yield (%) (75.3%) (82.5%)    Forecast Financials   Income Statement      Total Revenues 16 15      S,G & A (26) (38)      R&D (50) (57)      Other Income/ Expense - Net 0 1      EBIT - Normalised (60) (79)      Net Interest & Financial Items 3 9      Pre-tax Profits - Normalised (57) (70)      Income Before Taxes (57) (70)      Tax 0 0      Tax Rate (%) 0.0% 0.0%      Net Income - Reported (57) (70)      Net Income - Normalised (57) (70)     Per Share Data      EPS - Diluted (1.45) (1.56)      EPS - Basic (1.45) (1.56)      EPS - Normalised (diluted) (1.45) (1.56)      EPS - Normalised (basic) (1.45) (1.56)      Avg. Shares Outstanding - Diluted 39.1 44.7      Avg. Shares Outstanding - Basic 39.1 44.7      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Entereg(R) (alvimopan) Available for the Management of Postoperative Ileus   (Adolor)   09-Jun-2008 Adolor and GlaxoSmithKline Announce FDA Approval of Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)   (Adolor)   20-May-2008 Adolor and GlaxoSmithKline Announce FDA Approval of Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)   (GlaxoSmithKline)   20-May-2008 Adolor Provides Regulatory Update on Entereg(R) (alvimopan)   (Adolor)   09-May-2008 Progenics falls in POI race   (Progenics Pharmaceuticals)   12-Mar-2008 FDA Extends Review of NDA for ENTEREG(R) (alvimopan)   (Adolor)   08-Feb-2008 FDA Extends Review of NDA for Entereg® (alvimopan)   (GlaxoSmithKline)   08-Feb-2008 Adolor and GlaxoSmithKline Report Favorable FDA Advisory Committee Meeting for ENTEREG(R) (alvimopan) for the Management of Postoperative Ileus in Bowel Resection   (Adolor)   23-Jan-2008 GlaxoSmithKline and Adolor report favourable FDA Advisory Committee Meeting for Entereg® (alvimopan) for the Management of Postoperative Ileus in Bowel Resection   (GlaxoSmithKline)   23-Jan-2008 Adolor Announces Availability of Briefing Documents For January 23rd FDA Advisory Committee Meeting on Entereg(R) (alvimopan)   (Adolor)   18-Jan-2008 Adolor nearing pivotal FDA ruling   (Adolor)   10-Jan-2008 Adolor Announces Investigational New Drug Application for Novel Delta Agonist ADL5747   (Adolor)   28-Dec-2007 Adolor Initiates Phase 2a Study of Delta Agonist ADL5859 in Neuropathic Pain   (Adolor)   14-Dec-2007 Adolor and GlaxoSmithKline Announce FDA Advisory Committee to Review Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)   (Adolor)   28-Nov-2007 Adolor Corporation Initiates Second Phase 2 Study of Novel Delta Agonist   (Adolor)   18-Oct-2007 FDA To Continue Its Review of Requests for Release of Clinical Hold on Alvimopan (Entereg(R))   (Adolor)   13-Sep-2007 FDA Accepts for Review Complete Response to Approvable Letter for Entereg(R) (alvimopan) for POI   (Adolor)   28-Aug-2007 FDA Accepts for Review Complete Response to Approvable Letter for Entereg®(Alvimopan) for POI   (GlaxoSmithKline)   28-Aug-2007 Adolor Corporation Initiates First of Three Proof of Concept Studies of Novel Delta Opioid Agonist for the Management of Pain   (Adolor)   09-Jul-2007 GSK and Adolor Update Alvimopan (Entereg/Entrareg(R)) Development Program   (Adolor)   11-Jun-2007 GlaxoSmithKline and Adolor Update Alvimopan (Entereg/Entrareg®) Development Programme   (GlaxoSmithKline)   11-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Adolor ADL 10-0101 -   ADL 10-0116 -   ADL 1-0398 -   ADL 2-1294 loperamide   ADL5747 -   ADL5859 -   Arixtra fondaparinux sodium   Cannabinoid agonist program -   Entereg & hydrocodone alvimopan & hydrocodone   Entereg/Entrareg alvimopan   Kappa agonist program -   Mu agonist program -   Sterile Patch Program (LidoPAIN SP) lidocaine

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:52:32 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd